Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus (NCT07450716) | Clinical Trial Compass
Not Yet RecruitingEarly Phase 1
Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus
United States20 participantsStarted 2026-04
Plain-language summary
This study is designed to evaluate the safety and effectiveness of a low-level near-infrared LED light device for relieving itch. The device is non-invasive, does not break the skin, and does not produce heat. Near-infrared light has been used in other medical settings and is known to interact with skin and nerve pathways. In this study, researchers are examining whether this light can be safely applied to the skin and whether it may help reduce itch by affecting signals involved in itch sensation.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant is an adult at least 18 years-of-age.
✓. Participant meets the criteria for acute or chronic itch as defined below:
✓. Acute itch lasting less than 6 weeks.
✓. Chronic itch lasting more than 6 weeks.
✓. Participant is able and willing to comply with all the study visit, treatment, and evaluation schedules and requirements.
✓. Participant can understand and provide written informed consent.
✓. Participant does not have any concurrent injury or wound in their target treatment area.
✓. Participant is either untreated for their pruritus, or if on therapy, must have been maintained on a stable regimen of antipruritic treatments for the past 14 days prior to enrollment.
Exclusion criteria
✕. Participant has any active internal or cutaneous malignancy located within the proposed treatment area.
✕. Participant cannot provide informed consent or adhere to study schedule.
✕. Participant is actively tanning during the study course.
✕. Participant has melasma or another condition exacerbated by heat.
✕. Participant is on a photosensitizing medication, such as doxycycline or has a photosensitizing condition.
What they're measuring
1
Peak Pruritus Numerical Rating Scale (PP-NRS)
Timeframe: Once daily for 7 days prior to the first treatment visit; each treatment visit; once daily for 7 days after the final treatment visit--Days -7~6, Days 13~20.
✕. Patient is currently pregnant or breastfeeding.
✕. Participant has psychogenic pruritus, a diagnosed skin-picking (excoriation) disorder, or any other current psychiatric condition that, in the investigator's judgment, could interfere with informed consent, adherence to the study protocol, or safe participation.
✕. Participant has any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this study.